MODD · Modular Medical, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $14.70M | $12.88M | $9.06M | $7.73M | $4.08M | $3.03M |
| SG&A | $4.35M | $4.65M | $4.82M | $7.20M | $3.25M | $2.31M |
| Total Operating Expenses | $19.05M | $17.53M | $13.88M | $14.93M | $7.34M | $5.35M |
| D&A | $1.06M | $426.0K | $152.4K | $117.5K | $111.0K | $35.4K |
| Operating Income | ($19.05M) | ($17.53M) | ($13.88M) | ($14.93M) | ($7.34M) | ($5.35M) |
| Interest Expense | - | - | - | $2.75M | $0 | - |
| Income Tax | $2.0K | $2.0K | $1.6K | $1.6K | $1.6K | $1.6K |
| Net Income | ($18.82M) | ($17.47M) | ($13.88M) | ($18.63M) | ($7.38M) | ($5.32M) |
| EPS - Basic | ($15.30) | ($23.40) | ($82.20) | - | - | - |
| EPS - Diluted | ($15.30) | ($23.40) | ($82.20) | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.10M | $9.23M | $3.80M | $9.08M | $1.47M | $3.12M |
| Accounts Receivable | - | $142.0K | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $338.0K | $802.0K | $300.0K | - | - | - |
| Current Assets | $13.52M | $9.70M | $4.05M | $9.39M | $1.65M | $3.19M |
| Total Assets | $18.73M | $13.81M | $7.25M | $9.85M | $2.25M | $3.86M |
| Current Liabilities | $1.26M | $1.46M | $979.3K | $969.7K | $3.30M | $661.4K |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $1.66M | $2.27M | $2.17M | $1.01M | $3.52M | $980.1K |
| Stockholders' Equity | $17.08M | $11.54M | $5.08M | $8.84M | ($1.28M) | $2.88M |
| Retained Earnings | ($84.75M) | ($65.93M) | ($48.46M) | ($34.58M) | ($15.95M) | ($8.57M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($15.72M) | ($13.95M) | ($11.01M) | ($10.26M) | ($5.91M) | ($4.09M) |
| Investing Cash Flow | ($2.49M) | ($1.70M) | ($1.64M) | ($54.8K) | ($109.7K) | ($260.8K) |
| Financing Cash Flow | $22.08M | $21.09M | $7.37M | $17.92M | $4.36M | $924.0K |
| CapEx | $2.49M | $1.70M | $1.64M | $54.8K | $109.7K | $260.8K |
| Free Cash Flow | ($18.21M) | ($15.65M) | ($12.65M) | ($10.31M) | ($6.02M) | ($4.36M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.97 | 0.90 | 0.91 | 0.55 | 0.82 | 0.82 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -100.5% | -126.5% | -191.6% | -189.2% | -328.2% | -137.9% |
| Return on equity | -110.2% | -151.5% | -273.4% | -210.9% | 578.6% | -184.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 10.69 | 6.66 | 4.13 | 9.68 | 0.50 | 4.82 |
| Quick ratio | 10.69 | 6.66 | 4.13 | 9.68 | 0.50 | 4.82 |
| Cash ratio | 10.35 | 6.35 | 3.88 | 9.36 | 0.45 | 4.72 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | -5.4x | - | - |
| Equity multiplier | 1.10 | 1.20 | 1.43 | 1.11 | -1.76 | 1.34 |
| Liabilities / Assets | 0.09 | 0.16 | 0.30 | 0.10 | 1.57 | 0.25 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 70.9x | 107.7x | 58.3x | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -8.7% | -26.3% | 7.0% | -103.4% | -37.2% | -107.5% |
| Net income growth (YoY) | -7.8% | -25.9% | 25.5% | -152.5% | -38.7% | -109.5% |
| EPS growth (YoY) | 34.6% | 71.5% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -16.4% | -23.7% | -22.6% | -71.4% | -38.2% | -131.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 48.0% | 127.2% | -42.6% | - | - | -55.5% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Modular Medical against the 5 most active filers in the same SIC group.